Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
320 participants in 4 patient groups
There are currently no registered sites for this trial.
Central trial contact
Study Contact
Start date
May 30, 2024 • 10 months ago
Today
Apr 28, 2025
End date
Sep 29, 2028 • in 3 years
Lead Sponsor
Collaborating Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal